Dr. Lewis Schrager is vice president of scientific affairs at Aeras. He oversees and maintains key external relationships focused on research and development, including the regulatory affairs, global affairs, safety and pharmacovigilance and medical writing departments. He previously served chief of vaccine clinical review at the Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration. He previously worked for the National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health.
New vaccines are needed to combat mutating strains of tuberculosis, including multiple and extensively drug-resistant TB. Extensive international collaboration is needed to advance TB vaccine development, Dr. Lewis Schrager, vice president of scientific affairs at nonprofit biotech Aeras, write in this guest commentary.